Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Dermatologic

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or S├ęzary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD
Dermatologic
III
Zic, John
NCT02811783
VICCDERM1798

Aspirin in Preventing Colorectal Cancer in Patients with Colorectal Adenoma

Multiple Cancer Types

This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Colon, Rectal
II
Dai, Qi
NCT02965703
VICCGI17105

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Prostate

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Prostate
III
Moses, Kelvin
NCT03395197
VICCURO17115

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Multiple Cancer Types

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Lung, Small Cell
III
Iams, Wade
NCT03703297
VICCTHO1901

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: